An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2016
Price : $35 *
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Fluorouracil; Folinic acid; Irinotecan; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AbbVie
- 26 Sep 2016 Status changed from active, no longer recruiting to completed.
- 04 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Nov 2016.
- 04 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2016.